Krka DDLTS:0HLK 84 Current Ratio is 4.05 as of Mar. 2026, which is 12% above its 10-year median of 3.61. GuruFocus rates LTS:0HLK with a GF Score™ of 84/100 and a GF Value™ of €41.97 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 998 Drug Manufacturers companies, Krka DD ranks better than 78.36% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Krka DD's current ratio for the quarter that ended in Mar. 2026 was 4.05.
Krka DD has a current ratio of 4.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Krka DD's Current Ratio or its related term are showing as below:
LTS:0HLK'
s Current Ratio Range Over the Past 10 Years
Min: 2.48 Med: 3.61 Max: 4.69
Current: 4.05
During the past 13 years, Krka DD's highest Current Ratio was 4.69. The lowest was 2.48. And the median was 3.61.
LTS:0HLK's Current Ratio is ranked better than 78.36% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs LTS:0HLK: 4.05
Krka DD (LTS:0HLK) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Krka DD Current Ratio Related Terms
Krka DD Current Ratio Historical Data
* Premium members only.
The historical data trend for Krka DD's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HLK vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Current Ratio distribution charts can be found below:
* The bar in red indicates where Krka DD's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (LTS:0HLK) has a Current Ratio of 4.05 as of Mar. 2026. This is 12% above median its historical median of 3.61. Over the past decade, Krka DD's Current Ratio has ranged from 2.48 to 4.69. According to the industry distribution chart, Krka DD ranks #216 out of 998 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Krka DD's Current Ratio too high?
Krka DD's current Current Ratio of 4.05 is 12% above median its 10-year median of 3.61. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 4.69. The Drug Manufacturers industry median Current Ratio is 2.00. Krka DD's value of 4.05 is 102.5% above this industry median. Based on the distribution chart, Krka DD ranks #216 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #216 out of 998 companies for Current Ratio. This places Krka DD in the top 22% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Krka DD's value of 4.05 is 102.5% above this benchmark. Historically, Krka DD's own Current Ratio has ranged from 2.48 to 4.69 over the past decade. While the company's 10-year median is 3.61 vs. the industry median of 2.00, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Current Ratio of 4.05 is 102.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Current Ratio is 4.05, which is 12% above median its own 10-year median of 3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.97, compared to a current price of €64.80 — trading 54.4% above its estimated fair value. The current Current Ratio is 4.05, which is 12% above median its 10-year median of 3.61 and 102.5% above the Drug Manufacturers industry median of 2.00. Krka DD's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current Current Ratio is 4.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 54.4% above its estimated GF Value™ of €41.97.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for LTS:0HLK:
Current Ratio: 4.05 (12% above median its 10-year median of 3.61)
GF Value™: €41.97 vs. price of €64.80 (54.4% above fair value)
Industry Position: 102.5% above the Drug Manufacturers median (#216 of 998)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
84GF Score
Get the complete analysis for LTS:0HLK
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
